Publication: Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
dc.conference.date | MAR 30-APR 02, 2022 | |
dc.conference.title | European Lung Cancer Congress (ELCC) | |
dc.contributor.author | Garassino, M. C. | |
dc.contributor.author | Mazieres, J. | |
dc.contributor.author | Reck, M. | |
dc.contributor.author | Chouaid, C. | |
dc.contributor.author | Bischoff, H. | |
dc.contributor.author | Reinmuth, N. | |
dc.contributor.author | Cove-Smith, L. | |
dc.contributor.author | Mansy, T. | |
dc.contributor.author | Cortinovis, D. | |
dc.contributor.author | Migliorino, M. R. | |
dc.contributor.author | Delmonte, A. | |
dc.contributor.author | Sanchez, J. Garcia | |
dc.contributor.author | Velarde, L. E. Chara | |
dc.contributor.author | Bernabe, R. | |
dc.contributor.author | Paz-Ares, L. | |
dc.contributor.author | Perez, I. Diaz | |
dc.contributor.author | Trunova, N. | |
dc.contributor.author | Foroutanpour, K. | |
dc.contributor.author | Faivre-Finn, C. | |
dc.contributor.authoraffiliation | [Garassino, M. C.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy | |
dc.contributor.authoraffiliation | [Garassino, M. C.] Univ Chicago, Chicago, IL 60637 USA | |
dc.contributor.authoraffiliation | [Mazieres, J.] Inst Univ Canc Toulouse, Toulouse, France | |
dc.contributor.authoraffiliation | [Reck, M.] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany | |
dc.contributor.authoraffiliation | [Chouaid, C.] Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France | |
dc.contributor.authoraffiliation | [Bischoff, H.] Thoraxklin Heidelberg, Heidelberg, Germany | |
dc.contributor.authoraffiliation | [Reinmuth, N.] Asklepios Fachkliniken Munich Gauting, Thorac Oncol, Gauting, Germany | |
dc.contributor.authoraffiliation | [Cove-Smith, L.] Christie NHS Fdn Trust, Manchester, Lancs, England | |
dc.contributor.authoraffiliation | [Faivre-Finn, C.] Christie NHS Fdn Trust, Manchester, Lancs, England | |
dc.contributor.authoraffiliation | [Cove-Smith, L.] Manchester Univ Hosp Fdn Trust, Manchester, Lancs, England | |
dc.contributor.authoraffiliation | [Mansy, T.] South Tees Hosp NHS Fdn Trust, Middlesbrough, Cleveland, England | |
dc.contributor.authoraffiliation | [Cortinovis, D.] San Gerardo Hosp, ASST Monza, Oncol Unit, Monza Brianza, Italy | |
dc.contributor.authoraffiliation | [Migliorino, M. R.] San Camillo Forlanini Hosp, Rome, Italy | |
dc.contributor.authoraffiliation | [Delmonte, A.] Ist Romagnolo Studio Tumori IRST Dino Amadori, IRCCS, Meldola, Italy | |
dc.contributor.authoraffiliation | [Sanchez, J. Garcia] Hosp Arnau Vilanova, Fdn El Fomento Invest Sanitaria & Biomed Comunida, Med Oncol Dept, Valencia, Spain | |
dc.contributor.authoraffiliation | [Velarde, L. E. Chara] Hosp Univ Guadalajara, Guadalajara, Spain | |
dc.contributor.authoraffiliation | [Bernabe, R.] Hosp Univ Virgen Rocio, Seville, Spain | |
dc.contributor.authoraffiliation | [Paz-Ares, L.] Univ Complutense, CiberOnc, CNIO, Madrid, Spain | |
dc.contributor.authoraffiliation | [Paz-Ares, L.] Hosp Univ 12 Octubre, Madrid, Spain | |
dc.contributor.authoraffiliation | [Perez, I. Diaz] AstraZeneca, Gaithersburg, MD USA | |
dc.contributor.authoraffiliation | [Trunova, N.] AstraZeneca, Gaithersburg, MD USA | |
dc.contributor.authoraffiliation | [Foroutanpour, K.] AstraZeneca, Gaithersburg, MD USA | |
dc.contributor.authoraffiliation | [Faivre-Finn, C.] Univ Manchester, Manchester, Lancs, England | |
dc.contributor.funder | AstraZeneca | |
dc.date.accessioned | 2023-05-03T14:39:22Z | |
dc.date.available | 2023-05-03T14:39:22Z | |
dc.date.issued | 2022-04-02 | |
dc.identifier.doi | 10.1016/j.annonc.2022.02.135 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | http://www.annalsofoncology.org/article/S0923753422002514/pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/21892 | |
dc.identifier.wosID | 778453100110 | |
dc.issue.number | 2 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | S81-S82 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6) | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 33 | |
dc.wostype | Meeting Abstract | |
dspace.entity.type | Publication |